Linked Life Data

15570011

Source:http://linkedlifedata.com/resource/pubmed/id/15570011

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
22
pubmed:dateCreated
2004-11-30
pubmed:abstractText
Despite promising initial results, recent Phase III trials of the selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib ("Iressa"; AstraZeneca, Wilmington, Delaware) in advanced head and neck squamous cell carcinoma (HNSCC) have been equivocal. Cyclin D1, an EGFR target gene, is frequently overexpressed in HNSCC, has been implicated in its pathogenesis, and is strongly associated with poor prognosis in this disease. Therefore, we examined the relationship between deregulated cyclin D1 expression and sensitivity to gefitinib to determine whether this frequently occurring oncogenic change affected the cellular response to gefitinib.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
7764-74
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:15570011-Antineoplastic Agents, pubmed-meshheading:15570011-Blotting, Southern, pubmed-meshheading:15570011-Carcinoma, Squamous Cell, pubmed-meshheading:15570011-Cell Line, Tumor, pubmed-meshheading:15570011-Cell Proliferation, pubmed-meshheading:15570011-Cyclin D1, pubmed-meshheading:15570011-DNA, pubmed-meshheading:15570011-Dose-Response Relationship, Drug, pubmed-meshheading:15570011-Flow Cytometry, pubmed-meshheading:15570011-G1 Phase, pubmed-meshheading:15570011-Gene Expression Regulation, Neoplastic, pubmed-meshheading:15570011-Genetic Vectors, pubmed-meshheading:15570011-Head and Neck Neoplasms, pubmed-meshheading:15570011-Humans, pubmed-meshheading:15570011-Inhibitory Concentration 50, pubmed-meshheading:15570011-Prognosis, pubmed-meshheading:15570011-Protein Kinase Inhibitors, pubmed-meshheading:15570011-Quinazolines, pubmed-meshheading:15570011-Receptor, Epidermal Growth Factor, pubmed-meshheading:15570011-S Phase, pubmed-meshheading:15570011-Time Factors
pubmed:year
2004
pubmed:articleTitle
Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
pubmed:affiliation
Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't